{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:52:45Z","timestamp":1777553565076,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,18]]},"DOI":"10.7759\/cureus.21354","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:54:52Z","timestamp":1642499692000},"source":"Crossref","is-referenced-by-count":3,"title":["Olanzapine-Induced Parkinsonism and Akathisia: A Case Report"],"prefix":"10.7759","author":[{"given":"Varun","family":"Jaitpal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Gawande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2004.07.008","article-title":"A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition","volume":"129","author":"Malla A","year":"2004","unstructured":"Malla A, Norman R, Scholten D, Townsend L, Manchanda R, Takhar J, Haricharan R. A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatry Res. 2004, 129:159-69. 10.1016\/j.psychres.2004.07.008","journal-title":"Psychiatry Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S209284","article-title":"A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future","volume":"15","author":"Citrome L","year":"2019","unstructured":"Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019, 15:2559-69. 10.2147\/NDT.S209284","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.01.004","article-title":"A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia","volume":"185","author":"Lin CH","year":"2017","unstructured":"Lin CH, Wang FC, Lin SC, Huang YH, Chen CC. A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia. Schizophr Res. 2017, 185:80-7. 10.1016\/j.schres.2017.01.004","journal-title":"Schizophr Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890010203","article-title":"Dopamine receptors and the dopamine hypothesis of schizophrenia","volume":"1","author":"Seeman P","year":"1987","unstructured":"Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987, 1:133-52. 10.1002\/syn.890010203","journal-title":"Synapse"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman P","year":"2002","unstructured":"Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002, 47:27-38. 10.1177\/070674370204700106","journal-title":"Can J Psychiatry"},{"key":"ref6","article-title":"","author":"Stahl SM","year":"2013","unstructured":"Stahl SM. Stahl\u2019s Essential Psychopharmacology, 4th edition. Cambridge University Press, Cambridge; 2013. https:\/\/psycnet.apa.org\/record\/2013-20147-000."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1517\/14740330802423234","article-title":"Olanzapine: review of safety 2008","volume":"7","author":"Kantrowitz JT","year":"2008","unstructured":"Kantrowitz JT, Citrome L. Olanzapine: review of safety 2008. Expert Opin Drug Saf. 2008, 7:761-9. 10.1517\/14740330802423234","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin HW","year":"2012","unstructured":"Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012, 8:15-21. 10.3988\/jcn.2012.8.1.15","journal-title":"J Clin Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161208153644","article-title":"Revisiting antipsychotic-induced akathisia: current issues and prospective challenges","volume":"15","author":"Salem H","year":"2017","unstructured":"Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017, 15:789-98. 10.2174\/1570159X14666161208153644","journal-title":"Curr Neuropharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852915000838","article-title":"The clinical challenges of akathisia","volume":"20 Suppl 1","author":"Lohr JB","year":"2015","unstructured":"Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of akathisia. CNS Spectr. 2015, 20 Suppl 1:1-14; quiz 15-6. 10.1017\/S1092852915000838","journal-title":"CNS Spectr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(01)01251-3","article-title":"Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Shitij Kapur GR","year":"2001","unstructured":"Shitij Kapur GR. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Soc Biol Psychiatry. 2001, 50:873-83. 10.1016\/s0006-3223(01)01251-3","journal-title":"Soc Biol Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors","volume":"8","author":"Sykes DA","year":"2017","unstructured":"Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, Lane JR, Charlton SJ. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun. 2017, 8:763. 10.1038\/s41467-017-00716-z","journal-title":"Nat Commun"},{"key":"ref13","article-title":"","author":"Benjamin J","year":"2017","unstructured":"Benjamin J, Sadock HK. Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry. Wolters Kluwer, Alphen aan den Rijn; 2017. https:\/\/www.wolterskluwer.com\/en\/solutions\/ovid\/kaplan--sadocks-comprehensive-textbook-of-psychiatry-761."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane JM","year":"2010","unstructured":"Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010, 167:181-9. 10.1176\/appi.ajp.2009.07081221","journal-title":"Am J Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.832753","article-title":"Drug safety evaluation of olanzapine pamoate","volume":"12","author":"Sch\u00f6ttle D","year":"2013","unstructured":"Sch\u00f6ttle D, Kuhnigk O, Naber D. Drug safety evaluation of olanzapine pamoate. Expert Opin Drug Saf. 2013, 12:897-903. 10.1517\/14740338.2013.832753","journal-title":"Expert Opin Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/83812-olanzapine-induced-parkinsonism-and-akathisia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:35:54Z","timestamp":1707507354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/83812-olanzapine-induced-parkinsonism-and-akathisia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.21354","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}